BioSpace News Archive

OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE ® to treat mild-to-moderate COVID-19.

iCAD, Inc. today announced that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th , 2022.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

According to Emergen Research, the global electrotherapy market size was USD 950 Million in 2020 and is expected to reach USD 1.30 Billion in 2028 and register a revenue CAGR of 3.9% during the forecast period, 2021-2028.

PDS Biotechnology Corporation announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS Biotech.

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference at 1:00 p.m. ET on Thursday, Jan. 6, 2022.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2021, and other recent developments.

Sosei Group Corporation announces that in connection with the Collaboration and License Agreement with Neurocrine Biosciences, Inc. announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on 22 December 2021.

Novavax, Inc. and SK bioscience, Co. Limited announced the expansion of the companies’ collaboration and license agreements for NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine.